JFG
KYTX icon

Jefferies Financial Group’s Kyverna Therapeutics KYTX Stock Holding History

Jefferies Financial Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,920
Closed -$206K – 2105
2026
Q1 		$206K Sell
23,920
-8,081
-25% -$67.3K ﹤0.01% 1512
2025
Q4 		$301K Buy
32,001
+15,701
+96% +$117K ﹤0.01% 1495
2025
Q3 		$97.8K Buy
+16,300
New +$65.2K ﹤0.01% 1342

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Jefferies Financial Group's KYTX Position: Q2 2026 in Review

Jefferies Financial Group sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 23,920 shares — an estimated $206K sold.

Jefferies Financial Group first reported a position in KYTX in Q3 2025 and held it in 3 quarters. The position peaked at $301K in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Jefferies Financial Group reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 23,920 Kyverna Therapeutics shares in Q2 2026, an estimated $206K.
  • Jefferies Financial Group first reported a position in Kyverna Therapeutics in Q3 2025 and held it in 3 quarters.
  • Jefferies Financial Group's Kyverna Therapeutics position peaked at $301K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.